ClinicalTrials.gg
RecruitingNCT06752018INFOUpdated Feb 3, 2025

Inflammation's Impact on Heart Disease and Diabetes

An observational study in Inflammation, Obesity and Type 2 Diabetes and Obesity, sponsored by University of Aarhus. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Primary conditionObesityRegistry: InflammationReclassifiedWhy we changed it
Registry
Inflammation — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. Inflammation is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Aarhus · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Obesity by University of Aarhus — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University of Aarhus.

Planned enrollment
3rd of 14
250 · median 67
Started
2025
with 2 others
Observational
14 of 40
2 open now
Registered
37th of 40
by date

Among the 40 studies in Obesity by University of Aarhus, this one is the 3rd largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2025, is one of 14 observational ones, and was the 37th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 40 studies in Obesity by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Obesity by University of Aarhus, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate the inflammatory response associated with cardiometabolic diseases, and whether these can be reduced by ex vivo treatment with therapeutic agents. Briefly, the study involves two populations: healthy volunteers and severely obese patients undergoing weight-loss surgery. The main questions the study seeks to address are:

  1. To investigate if the therapeutic agents modulate the inflammatory response linked to obesity and cardiometabolic disease?
  2. What underlying factors contribute to variations in individual responses?

Researchers will examine differences between healthy participants and those undergoing weight-loss surgery to assess the potential impact of weight loss on responsiveness and overall outcomes.

Participants will:

  • Undergo initial testing to evaluate their baseline response.
  • Provide samples during surgery for further analysis.
  • Participate in follow-up assessments to track changes over time.
Read the detailed description

The goal of this observational study is to investigate the relationship between treatment responsiveness and inflammation both systemically in blood, and peripherally in tissue biopsies, focusing on its relevance to cardiometabolic disease and associated conditions. The study aims to develop a predictive model to identify individuals most likely to benefit from anti-inflammatory treatments, thus supporting personalized therapeutic strategies.

Main research questions:

  1. To investigate if the therapeutic agents modulate the inflammatory response linked to obesity and cardiometabolic disease
  2. To determine the underlying factors that contribute to variations in individual responses to anti-inflammatory drugs

Study design:

The study will involve two participant groups:

  • Healthy control group, composedrised of normal weight individuals
  • Obese adult patients, scheduled to undergo bariatric surgery.

Participant procedures:

  • Baseline testing: An initial test will evaluate treatment responsiveness.
  • Tissue sampling: Tissue biopsies are obtained during surgery and undergo detailed analyses, including ex vivo treatments
  • Follow-up assessments: Participants will be reassessed a year after surgery to evaluate long-term outcomes.

Methods:

  • Molecular studies: Whole blood and peripheral tissue biopsies (adipose tissue, liver, muscle and intestinal biopsies) will be analyzed to identify cellular and molecular pathways associated with treatment responsiveness.
  • Predictive modeling: Clinical, molecular, and biochemical data will be integrated to create a model predicting individual responsiveness.
  • Insulin sensitivity analysis: Advanced imaging techniques will measure tissue-specific glucose uptake.

Hypotheses: Impaired ability to regulate the inflammatory response correlates with cardiometabolic disease.

Anticipated Outcomes:

The study seeks to support precision medicine approaches for addressing cardiometabolic disease.

This research builds on previous findings about the role of inflammation in cardiometabolic dysfunction. By differentiating responders from non-responders, the study aims to support targeted therapeutic strategies for inflammation and cardiometabolic health.

03

Conditions studied

  • Inflammation
  • Obesity and Type 2 Diabetes
  • Obesity
  • Metabolic Syndrome
  • Anti-Inflammatory Agents

Keywords

  • Disease
  • Overweight
  • overnutrition
  • body weight
  • Insulin resistance
  • Inflammation
  • Anti-Inflammatory Agents
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 250 is above the median of 115 across 2,159 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammation. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy controls and obese patients, scheduled to undergo bariatric surgery without a pre-surgical diet

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals willing and able to give appropriate oral and written
  • Men and women over 18 years of age.
  • Correct (BMI) (Lean controls: 18.5-24.9 kg/m2. Obese gastric bypass patients: 35-50 kg/m2)

Exclusion criteria

Exclusion Criteria:

  • The individual does not follow instructions given in the research study.
  • Pregnancy.
  • Significant gastrointestinal problems.
  • Use of tobacco.
  • The individual consumed alcohol within two days prior to the study visit
  • Active cancer within 5 years.
  • Use of dietary supplements that impact the inflammatory resolution process (e.g., fish oils), and the person is not willing to discontinue the use of the supplements 1 week prior to the visits.
  • Underlying cardiometabolic disease, or medication related to such disease (e.g., blood pressure medication, insulin to treat diabetes, etc.).
  • Underlying inflammatory disease, or medication related to such disease.
  • The individual states that they have increased bleeding tendency or are using anti-coagulant (blood-thinning) medication.
  • For obese patients only: The individual has lost more than 8% of his/her body weight since their clinical referral for surgery or has lost more than 3% of his/her body weight in the 4 months leading up to surgery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Obese gastric bypass patients

    Procedure: Gastric bypass

  • Lean healthy controls

Interventions

  • ProcedureGastric bypass

    Roux-en-Y gastric bypass or sleeve gastrectomy

07

What researchers measure

Primary outcomes

  1. Whole blood ROS prooduction

    The primary endpoint of the study is the therapeutic agent-induced reduction in reactive oxygen species (ROS) production in whole blood, following stimulation with N-Formylmethionyl-leucyl-phenylalanine (fMLP), escherichia coli (E. coli), and phorbol myristate acetate (PMA).

    Time frame: At baseline and 1 year post surgery

  2. Whole blood ROS production

    The primary endpoint of the study is the therapeutic agent-induced reduction in ROS production in whole blood, following stimulation with fMPL, E. coli, or PMA

    Time frame: At the time of enrollment

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2030, 71 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 71 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2024
First posted
Dec 30, 2024
StartActual
Jan 30, 2025
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06752018
Responsible party
Sponsor
First posted
Dec 30, 2024
Start date
Jan 30, 2025
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Feb 3, 2025

Study contacts

Emma Börgeson, MSc
Contact
emma.borgeson@biomed.au.dk
+45 9352 2984
Emma Börgeson, Dr., PhD, MSc
principal investigator · University of Aarhus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion